News Results
There are 797,970 News Results
Oct 26, 2022
Hess Corporation (NYSE: HES) today reported net income of $515 million, or $1.67 per common share, in the third quarter of 2022, compared with net income of $115 million, or...
Jun 1, 2023
NGL Energy Partners LP (NYSE:NGL) (“NGL,” “our,” “we,” or the “Partnership”) today reported its fourth quarter and full year fiscal 2023 results. Highlights for the fiscal year and quarter ended...
Jul 26, 2023
Hess Corporation (NYSE: HES) today reported net income of $119 million, or $0.39 per share, in the second quarter of 2023, compared with net income of $667 million, or $2.15...
Jan 31, 2024
Hess Corporation (NYSE: HES) today reported net income of $413 million, or $1.34 per share, in the fourth quarter of 2023, compared with net income of $497 million, or $1.61...
Feb 9, 2024
NGL Energy Partners LP (NYSE:NGL) (“NGL,” “we,” “us,” “our,” or the “Partnership”) today reported its third quarter Fiscal 2024 financial results. Highlights include: Net income for the third quarter of...
May 16, 2024
Chemtrade Logistics Income Fund (TSX: CHE.UN) (“Chemtrade” or the “Fund”) today announced results for the three months ended March 31, 2024. The financial statements and MD&A will be available on...
May 23, 2024
Biomarker Analyses from Pivotal Phase 3 CLEAR Trial in Patients with Advanced Renal Cell Carcinoma Will Be Featured in an Oral Presentation
Jul 31, 2024
Hess Corporation (NYSE: HES) today reported net income of $757 million, or $2.46 per share, in the second quarter of 2024, compared with net income of $119 million, or $0.39...
Aug 20, 2024
RYBREVANT(® )plus LAZCLUZE(TM) is the first and only chemotherapy-free regimen showing superior progression-free survival versus osimertinib
Sep 4, 2024
Late-breaking results from the Phase 3 LEAP-012 trial offer further insight into the treatment of patients with unresectable, non-metastatic hepatocellular carcinoma (HCC); data are selected for ESMO Presidential Symposium Session
